Figure 3.

In vivo efficacy of anti-PD-L1 clones 11B12-1 and 12F1-1 in a Syrian hamster model of pancreatic ductal adenocarcinoma. (A) Schematic of treatment scheme. HapT1 (heterotopic PDAC) bearing Syrian hamsters (n=4 per group) were intraperitoneally injected with PBS (Mock), IgG isotype controls (800 µg) or Syrian hamster anti-PD-L1 (11B12-1 or 12F1-1) at three doses (100, 300 or 800 µg) every three days for a total of 6 injections. (B) Mean percentage change in tumour volume for 11B12-1 (upper) and 12F1-1(lower) treated hamsters and respective controls with statistical significance shown to the right. (C) Individual tumour growth curves. (D) Percentage change in weight of hamsters after treatment with anti-PD-L1 clone’s 11B12-1 and 12F1-1. (E) Percentage of tumour necrosis and CD8⁺ cells in spleens of hamsters as determined by histopathological analysis and flow cytometry respectively. Data is normalized to day 0. All data and error bars are presented as mean ± SEM. Statistical significance for tumour growth controls was calculated using two-way mixed model ANOVA. All other data was calculated for statistical significance using an unpaired t-test with Welch’s correction. *p < 0.05, ns not significant.